Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1982 5
1983 4
1984 5
1985 10
1986 9
1987 7
1988 13
1989 14
1990 16
1991 5
1992 16
1993 14
1994 22
1995 34
1996 21
1997 35
1998 43
1999 49
2000 63
2001 51
2002 76
2003 115
2004 127
2005 182
2006 235
2007 214
2008 312
2009 370
2010 467
2011 524
2012 633
2013 743
2014 799
2015 953
2016 1049
2017 1154
2018 1326
2019 1602
2020 1984
2021 2157
2022 2522
2023 2515
2024 2896
2025 1699

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,469 results

Results by year

Filters applied: . Clear all
Page 1
Targeted MYC2 stabilization confers citrus Huanglongbing resistance.
Zhao P, Yang H, Sun Y, Zhang J, Gao K, Wu J, Zhu C, Yin C, Chen X, Liu Q, Xia Q, Li Q, Xiao H, Sun HX, Zhang X, Yi L, Zhou C, Kliebenstein DJ, Fang R, Wang X, Ye J. Zhao P, et al. Among authors: zhou c. Science. 2025 Apr 11;388(6743):191-198. doi: 10.1126/science.adq7203. Epub 2025 Apr 10. Science. 2025. PMID: 40208996
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. Felip E, et al. Among authors: zhou c. J Clin Oncol. 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681. Online ahead of print. J Clin Oncol. 2025. PMID: 40446184
Carbon-sequestration gradient insulation composites.
Sarkar A, Zhu L, Petit D, Islam A, Guo Z, Zhou C, Armstrong JN, Ren S. Sarkar A, et al. Among authors: zhou c. Cell Rep Phys Sci. 2024 Oct 16;5(10):102222. doi: 10.1016/j.xcrp.2024.102222. Epub 2024 Sep 27. Cell Rep Phys Sci. 2024. PMID: 40444255 Free PMC article.
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.
Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y, Zhang Y, Cheng Y, Pan H, Zhang X, Cui J, Wang L, Chen X, Li X, Wang Z, Wang Q, He J, Wang M, Yan I, Qian L, Xu M, Huang X, Sun C, Cai J, Wu Q, Ballinger M, Kaul M, Srivastava MK. Zhou C, et al. Nat Med. 2025 May 16. doi: 10.1038/s41591-025-03658-y. Online ahead of print. Nat Med. 2025. PMID: 40379995
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer.
Zha Z, Liu C, Yan M, Chen C, Yu C, Chen Y, Zhou C, Li L, Li YC, Yamaguchi H, Ye L, Liu T, Wang YN, Lee HH, Yang WH, Chan LC, Ke B, Hsu JL, Ding L, Ji D, Pan P, Meng Y, Pu Y, Liu L, Hung MC. Zha Z, et al. Among authors: zhou c. Signal Transduct Target Ther. 2025 Apr 18;10(1):124. doi: 10.1038/s41392-025-02206-x. Signal Transduct Target Ther. 2025. PMID: 40246819 Free PMC article.
22,469 results
You have reached the last available page of results. Please see the User Guide for more information.